You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Oriola Q2’24: Sales growth in both segments
Af Rauli Juva
Oriola’s Q2 earnings were quite in line with our estimates and the guidance for the whole year of 2024 remained unchanged. The joint venture company in Sweden performed better than we expected after two very weak quarters. CEO Katarina Gabrielson comments on the Q2 result in this interview.
Content:
00:00 Intro
00:09 Prohibited sale of Svensk dos AB
01:33 Q2 highlights
02:18 Growth in sales and invoicing
03:00 Joint venture company in Sweden
04:23 Outlook for dose dispensing business in Sweden
5 forudsigelser for aktiemarkedet i 2025
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
GomSpace – Management Q&A
Vis alle videoer